Financhill
Buy
69

CAH Quote, Financials, Valuation and Earnings

Last price:
$145.56
Seasonality move :
4.77%
Day range:
$136.71 - $147.27
52-week range:
$93.17 - $147.27
Dividend yield:
1.39%
P/E ratio:
27.15x
P/S ratio:
0.16x
P/B ratio:
--
Volume:
4M
Avg. volume:
2.8M
1-year change:
42.44%
Market cap:
$35.2B
Revenue:
$226.8B
EPS (TTM):
$5.36

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CAH
Cardinal Health
$55.3B $2.15 0.69% 108.11% $144.87
BIO
Bio-Rad Laboratories
$573.2M $1.78 -0.61% -86.56% $353.17
BSX
Boston Scientific
$4.6B $0.67 18.76% 229.31% $116.12
COR
Cencora
$75.8B $4.10 9.59% 57.95% $297.49
MASI
Masimo
$367.8M $1.21 -25.37% 192.38% $195.70
MCK
McKesson
$94.2B $9.83 19.22% 19.81% $709.65
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CAH
Cardinal Health
$145.53 $144.87 $35.2B 27.15x $0.51 1.39% 0.16x
BIO
Bio-Rad Laboratories
$240.43 $353.17 $6.7B -- $0.00 0% 2.64x
BSX
Boston Scientific
$103.19 $116.12 $152.6B 75.32x $0.00 0% 8.75x
COR
Cencora
$290.43 $297.49 $56.3B 41.31x $0.55 0.73% 0.19x
MASI
Masimo
$163.65 $195.70 $8.8B 116.80x $0.00 0% 4.23x
MCK
McKesson
$706.77 $709.65 $88.6B 32.36x $0.71 0.39% 0.27x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CAH
Cardinal Health
164.81% 0.200 26.51% 0.46x
BIO
Bio-Rad Laboratories
15.46% 1.030 13.06% 4.53x
BSX
Boston Scientific
32.79% 1.029 -- 0.46x
COR
Cencora
97.3% 0.081 18.65% 0.51x
MASI
Masimo
42.11% 1.411 8.64% 1.08x
MCK
McKesson
162.58% 0.870 11.1% 0.46x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CAH
Cardinal Health
$1.9B $530M 53.16% -- 0.99% -$499M
BIO
Bio-Rad Laboratories
$341.9M $58.3M -20.67% -23.87% -134.35% $81.2M
BSX
Boston Scientific
$3.2B $937M 6.43% 8.96% 19.02% $1.2B
COR
Cencora
$2.6B $807.5M 21.96% 155.22% 0.84% -$2.8B
MASI
Masimo
$244.7M -$54.6M -14.23% -23.05% -58.55% $47.5M
MCK
McKesson
$3.3B $1.3B 67.6% -- 1.36% -$2.6B

Cardinal Health vs. Competitors

  • Which has Higher Returns CAH or BIO?

    Bio-Rad Laboratories has a net margin of 0.72% compared to Cardinal Health's net margin of -107.24%. Cardinal Health's return on equity of -- beat Bio-Rad Laboratories's return on equity of -23.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    CAH
    Cardinal Health
    3.51% $1.65 $4.7B
    BIO
    Bio-Rad Laboratories
    51.23% -$25.57 $7.8B
  • What do Analysts Say About CAH or BIO?

    Cardinal Health has a consensus price target of $144.87, signalling downside risk potential of -0.45%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $353.17 which suggests that it could grow by 46.89%. Given that Bio-Rad Laboratories has higher upside potential than Cardinal Health, analysts believe Bio-Rad Laboratories is more attractive than Cardinal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    CAH
    Cardinal Health
    9 5 0
    BIO
    Bio-Rad Laboratories
    3 2 0
  • Is CAH or BIO More Risky?

    Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 0.999, suggesting its less volatile than the S&P 500 by 0.087999999999999%.

  • Which is a Better Dividend Stock CAH or BIO?

    Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.39%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CAH or BIO?

    Cardinal Health quarterly revenues are $55.3B, which are larger than Bio-Rad Laboratories quarterly revenues of $667.5M. Cardinal Health's net income of $400M is higher than Bio-Rad Laboratories's net income of -$715.8M. Notably, Cardinal Health's price-to-earnings ratio is 27.15x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.16x versus 2.64x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CAH
    Cardinal Health
    0.16x 27.15x $55.3B $400M
    BIO
    Bio-Rad Laboratories
    2.64x -- $667.5M -$715.8M
  • Which has Higher Returns CAH or BSX?

    Boston Scientific has a net margin of 0.72% compared to Cardinal Health's net margin of 14.45%. Cardinal Health's return on equity of -- beat Boston Scientific's return on equity of 8.96%.

    Company Gross Margin Earnings Per Share Invested Capital
    CAH
    Cardinal Health
    3.51% $1.65 $4.7B
    BSX
    Boston Scientific
    68.84% $0.45 $32.6B
  • What do Analysts Say About CAH or BSX?

    Cardinal Health has a consensus price target of $144.87, signalling downside risk potential of -0.45%. On the other hand Boston Scientific has an analysts' consensus of $116.12 which suggests that it could grow by 12.53%. Given that Boston Scientific has higher upside potential than Cardinal Health, analysts believe Boston Scientific is more attractive than Cardinal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    CAH
    Cardinal Health
    9 5 0
    BSX
    Boston Scientific
    23 4 0
  • Is CAH or BSX More Risky?

    Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

  • Which is a Better Dividend Stock CAH or BSX?

    Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.39%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CAH or BSX?

    Cardinal Health quarterly revenues are $55.3B, which are larger than Boston Scientific quarterly revenues of $4.7B. Cardinal Health's net income of $400M is lower than Boston Scientific's net income of $674M. Notably, Cardinal Health's price-to-earnings ratio is 27.15x while Boston Scientific's PE ratio is 75.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.16x versus 8.75x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CAH
    Cardinal Health
    0.16x 27.15x $55.3B $400M
    BSX
    Boston Scientific
    8.75x 75.32x $4.7B $674M
  • Which has Higher Returns CAH or COR?

    Cencora has a net margin of 0.72% compared to Cardinal Health's net margin of 0.6%. Cardinal Health's return on equity of -- beat Cencora's return on equity of 155.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    CAH
    Cardinal Health
    3.51% $1.65 $4.7B
    COR
    Cencora
    3.14% $2.50 $8.5B
  • What do Analysts Say About CAH or COR?

    Cardinal Health has a consensus price target of $144.87, signalling downside risk potential of -0.45%. On the other hand Cencora has an analysts' consensus of $297.49 which suggests that it could grow by 2.43%. Given that Cencora has higher upside potential than Cardinal Health, analysts believe Cencora is more attractive than Cardinal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    CAH
    Cardinal Health
    9 5 0
    COR
    Cencora
    9 6 0
  • Is CAH or COR More Risky?

    Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Cencora has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.596%.

  • Which is a Better Dividend Stock CAH or COR?

    Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.39%. Cencora offers a yield of 0.73% to investors and pays a quarterly dividend of $0.55 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Cencora pays out 27.58% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CAH or COR?

    Cardinal Health quarterly revenues are $55.3B, which are smaller than Cencora quarterly revenues of $81.5B. Cardinal Health's net income of $400M is lower than Cencora's net income of $488.6M. Notably, Cardinal Health's price-to-earnings ratio is 27.15x while Cencora's PE ratio is 41.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.16x versus 0.19x for Cencora. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CAH
    Cardinal Health
    0.16x 27.15x $55.3B $400M
    COR
    Cencora
    0.19x 41.31x $81.5B $488.6M
  • Which has Higher Returns CAH or MASI?

    Masimo has a net margin of 0.72% compared to Cardinal Health's net margin of -58.2%. Cardinal Health's return on equity of -- beat Masimo's return on equity of -23.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    CAH
    Cardinal Health
    3.51% $1.65 $4.7B
    MASI
    Masimo
    40.74% -$6.52 $1.8B
  • What do Analysts Say About CAH or MASI?

    Cardinal Health has a consensus price target of $144.87, signalling downside risk potential of -0.45%. On the other hand Masimo has an analysts' consensus of $195.70 which suggests that it could grow by 19.58%. Given that Masimo has higher upside potential than Cardinal Health, analysts believe Masimo is more attractive than Cardinal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    CAH
    Cardinal Health
    9 5 0
    MASI
    Masimo
    4 3 0
  • Is CAH or MASI More Risky?

    Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

  • Which is a Better Dividend Stock CAH or MASI?

    Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.39%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CAH or MASI?

    Cardinal Health quarterly revenues are $55.3B, which are larger than Masimo quarterly revenues of $600.7M. Cardinal Health's net income of $400M is higher than Masimo's net income of -$349.6M. Notably, Cardinal Health's price-to-earnings ratio is 27.15x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.16x versus 4.23x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CAH
    Cardinal Health
    0.16x 27.15x $55.3B $400M
    MASI
    Masimo
    4.23x 116.80x $600.7M -$349.6M
  • Which has Higher Returns CAH or MCK?

    McKesson has a net margin of 0.72% compared to Cardinal Health's net margin of 0.92%. Cardinal Health's return on equity of -- beat McKesson's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CAH
    Cardinal Health
    3.51% $1.65 $4.7B
    MCK
    McKesson
    3.45% $6.95 $5.3B
  • What do Analysts Say About CAH or MCK?

    Cardinal Health has a consensus price target of $144.87, signalling downside risk potential of -0.45%. On the other hand McKesson has an analysts' consensus of $709.65 which suggests that it could grow by 0.41%. Given that McKesson has higher upside potential than Cardinal Health, analysts believe McKesson is more attractive than Cardinal Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    CAH
    Cardinal Health
    9 5 0
    MCK
    McKesson
    10 3 0
  • Is CAH or MCK More Risky?

    Cardinal Health has a beta of 0.662, which suggesting that the stock is 33.768% less volatile than S&P 500. In comparison McKesson has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.469%.

  • Which is a Better Dividend Stock CAH or MCK?

    Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.39%. McKesson offers a yield of 0.39% to investors and pays a quarterly dividend of $0.71 per share. Cardinal Health pays 58.57% of its earnings as a dividend. McKesson pays out 10.46% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CAH or MCK?

    Cardinal Health quarterly revenues are $55.3B, which are smaller than McKesson quarterly revenues of $95.3B. Cardinal Health's net income of $400M is lower than McKesson's net income of $879M. Notably, Cardinal Health's price-to-earnings ratio is 27.15x while McKesson's PE ratio is 32.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.16x versus 0.27x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CAH
    Cardinal Health
    0.16x 27.15x $55.3B $400M
    MCK
    McKesson
    0.27x 32.36x $95.3B $879M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Palantir Stock a Millionaire Maker?
Is Palantir Stock a Millionaire Maker?

Palantir (NASDAQ:PLTR) has shot upward over the last year and…

Is QuantumScape a Buy Now?
Is QuantumScape a Buy Now?

QuantumScape (NYSE:QS) is an innovative EV battery company that specializes…

Is Vertex Stock Still a Good Buy?
Is Vertex Stock Still a Good Buy?

Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…

Stock Ideas

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Buy
59
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 38x

Alerts

Buy
62
RGC alert for May 2

Regencell Bioscience Holdings [RGC] is up 20.58% over the past day.

Sell
36
WGS alert for May 2

GeneDx Holdings [WGS] is down 6.85% over the past day.

Sell
42
VICR alert for May 2

Vicor [VICR] is down 1.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock